Undisclosed Antibody Program

About Orega Biotech

Orega Biotech is a private, preclinical to clinical-stage biotech focused on discovering and developing novel immunotherapies for cancer. The company leverages deep academic roots in immunology to identify and validate new targets, such as CD39, which regulates the immunosuppressive adenosine pathway in the tumor microenvironment. Its asset-centric strategy relies on early partnerships for development and commercialization, evidenced by significant licensing deals with Innate Pharma/AstraZeneca and Genmab. While pre-revenue, its partnered lead asset provides validation and de-risks its pipeline approach.

About Atengen

Atengen is pioneering a groundbreaking anti-angiogenic strategy that targets a specific receptor on tumor blood vessels to treat solid tumors. Founded in 2018 and based in Cambridge, MA, the company leverages a novel therapeutic target to develop both small molecule and antibody therapies intended to starve tumors by destroying their blood supply. This approach aims to be broadly applicable across many cancer types while minimizing resistance and off-target effects. The company is in the pre-clinical stage, supported by a world-class Scientific Advisory Board with deep expertise in oncology, angiogenesis, and drug development.

Therapeutic Areas

Other Undisclosed Drugs